Year In Review: Is Big Pharma Getting Smaller? Cost-Cutting Fails To Revive Rx Stocks
Executive Summary
As the pharmaceutical industry wades through its second spate of major restructuring initiatives in the last three years, investors may be weighing whether the programs reflect efforts to improve efficiency in the face of short-term setbacks, or suggest a more fundamental long-term downsizing of the brand industry
You may also be interested in...
Schering Looks Overseas, Under Couch To Sustain Growth As Vytorin Stumbles
Schering-Plough's strategy for reducing its elevated cholesterol worries depends on the firm capitalizing on one industry trend while bucking a few others
Schering Looks Overseas, Under Couch To Sustain Growth As Vytorin Stumbles
Schering-Plough's strategy for reducing its elevated cholesterol worries depends on the firm capitalizing on one industry trend while bucking a few others
Novartis Cuts 2,500 More Jobs In Drive To Save $1.6 Billion By 2010
Novartis will cut another 2,500 full-time positions by the end of 2008, 1,700 of them from its pharmaceuticals business, as part of a plan to put the division back on its feet after a rocky 2007, CEO Daniel Vasella announced Dec. 13